The Non-Small Cell Lung Cancer (NSCLC) market will undergo considerable growth from $5.1 billion in 2013 to $7.9 billion in 2020 at a Compound Annual Growth Rate (CAGR) of 6.6%. See more at- http://mrr.cm/Z7K
Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market
Non-Small Cell Lung
Cancer Market to 2020
- New Theranies to
Drive Growth in an
Category : Pharma 8. Healthcare
AH wqaxznd mg»: mentioned on mm was among lumen mwecuvr awnevx
; www. MarketResearcl1}1epur| s.cum
Introduction to Report
- Launch Date: July 31,2014
- Number of Pages: 143
- Geography Coverage: Global
- Available Format: PDF
-Price For Single User License: USD 3,500
-Price For Site User License: USD 7,000
-Price For Global User License: USD 10,500
-Delivery 1'Ime: Within 24 Hours (During Working Days)
$3 www. MarketResearchReports. com
About the Report
"Non-Small Cell Lung Cancer Market m 2020 - New
Yherapies m Enhance Treatment Segmentation and Drive
Growth in an Increasingly Competitive Market" report
focuses on the increasing differentiation between the
three main NSCLC subtypes: squamous cell,
adenocarcinoma, and large cell carcinoma.
The report assesses the current NSCLC market and
predicts market trends to 2020, analyxing key drivers and
www. MarketResearchReports. com
-The value of the Non-Small Cell Lung Cancer (NSCLC)
market is expected to increase significantly over the
forecast period across the leading eight developed
nations, from $5.1 billion in 2013 to $7.9 billion in 2020.
-This equates to a Compound Annual Growth Rate (CAGR)
of 6.6%. Growth will be driven by novel therapies entering
the squamous cell carcinoma market segment, which is
currently lacking effective treatment, unlike the non-
squamous market segment.
-New second-line therapies include immunostimulants
such as ramucirumab and nivolumab, which have shown
clinical beneﬁts, but which will face difﬁculties due to the
increasingly crowded second-line setting. Currently,
pharmaceutical treatment is limited to late-stage patients.
Research Finding Continues. ..
-Over the forecast period to 2020, several new additions
to the NSCLC treatment paradigm will transform the
treatment landscape. Many of these will he monoclonal
Antibodies (mAhs), which instigate an immune response
to the tumor rather than directly affecting cancer cells.
-Squamous cell hinology accounts for approximately 30%
of the NSCLC population, and pipeline products, such as
Vervoy (ipilimumah) in the ﬁrst-line treatment and
nivolumah in the second-line, will add greater diversity to
the treatment algorithm, with both having shown clinical
beneﬁts in early-stage trials.
-A disease introduction, which defines the disease and
looks at symptoms, diagnosis and treatment
-Analysis of the NSCLC marketed landscape, including a
comparison of the efﬁcacy and safety of the most
prominent brands, as well as the unmet needs of NSCLC
-Detailed analysis of the NSCLC pipeline, covering among
other parameters, drug distribution by Phase, molecule
type and mechanism of action. The NSCLC clinical trial
landscape is analyxed with particular emphasis on failure
rates across different trial Phases, as well as the trends in
clinical trial site, duration and primary endpoint.
-This section also includes proﬁles and single product
forecasts for the most promising pipeline drugs.
. Scope Continues. ..
-An epidemiological forecast of the major NSCLC markets,
In which projected values Include total and treated
-An In-depth forecanlng model for the NSCLC market,
which considers the current marketed therapies In
‘ ‘‘ addition to the potential entry of new products to the
market. The model comprises a projected outcome with
performance of pipeline therapies.
-Analysis of strategic consolidations within the NSCLC
Indication, Including co-development and licensing
-An overview of the drivers of and barriers to the NSCLC
‘ high and low variance results depending on the potential
www. MarketResearchReports. com
2. Marketed Products
3. NSCLC Pipeline
4. Market Forecast
5. Strategic consolidations
For more umhsvquﬂnl wan mun! meme nu snne
mgaqgxzm ». .,g. ;_m. nm. ,a 0., im: shd_- mpug aan. _.u m}nhc1w-Vuwnlrx
:5 www. MarketResearchReports. com
-Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
For Any (. ‘uslun| iL1lion Related query v‘ ‘ Ideal‘/ enter as
1m : www. rnarketrese.1rcl1re m. com id. ea—cenler
How To Buy This Report‘?
Visit following URL to see Table of Content and
purchase this publication:
http: IImrr. cmlZ7K
About Market Research Reports, Inc.
Market Research Fleports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redeﬁned".
Contac Amitava Sen
' f mrketre rch . m
+1 302-703-7737 (USA) +91—8762746600 (India)
M ; , www. MarketResearchReports. com